Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine vs one-dose vs four-day dexamethasone for prevention of chemotherapy-induced nausea and vomiting in pancreatic cancer patients receiving modified FOLFIRINOX
TCTR20230307001Phase 3Unknown
- Sponsor
- Hathaipat Veerawatananan
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of olanzapine and dexamethasone in pancreatic cancer (PC) and chemotherapy-induced nausea and vomiting (CINV) (3 arms), sponsored by Hathaipat Veerawatananan. Status: unknown.
02
Drugs
olanzapinedexamethasone
03
Conditions
pancreatic cancer (PC)chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on TCTR20230307001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230307001.